Navigation Links
Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
Date:9/21/2009

er the first cycle of treatment, and dose escalation continues.

"We are very encouraged by the tolerability of MT110 observed in this heavily pre-treated population of cancer patients and look forward to updating our results as we continue to increase the dose," commented Prof. Walter Fiedler from the University Hospital of Hamburg-Eppendorf, Germany, and principal investigator of the study.

"The interim phase 1 results and activity of MT110 at the current dose level are what we expected based on our preclinical data," commented Christian Itin, CEO of Micromet. "We are now looking forward to exploring the clinical activity of MT110 at higher dose levels."

MT110 is the second BiTE antibody undergoing clinical investigation. Micromet also has ongoing trials for blinatumomab (MT103), including a phase 2 trial for acute lymphoblastic leukemia (ALL) and a phase 1 trial for non-Hodgkin's lymphoma.

(1) Fiedler, W. et al. (2009) Safety and pharmacology of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer. ECCO/ESMO Meeting, Berlin, Abstract No. 1254

About BiTE Antibodies

BiTE(R) antibodies are the first T cell engaging antibodies to show clinical benefit in cancer patients, representing a new approach to cancer therapy. While previous attempts have shown the potential for the body's cell destroying T cells to treat cancer, these therapies have been hampered by the cancer cells' ability to avoid recognition by T cells. BiTE antibodies engage T cells to attack cancer cells anywhere in the body.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its propriet
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Grace Century, ... and healthcare projects, announces the addition of Dr. ... to its advisory team. Dr. Siddiqui will provide further ... , A graduate of University College Medical School ... degreed in medicine in 2001. With further certification as ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... CHESTER, Pa., April 1, 2008 VWR International,LLC, ... that it,has acquired Jencons (Scientific) Limited, a UK ... the UK,s largest suppliers of laboratory equipment,and consumables ... company also has,operations in Ireland, Kenya and North ...
... and MONTREAL, April 1 /PRNewswire-FirstCall/ - AEterna,Zentaris ... a global biopharmaceutical company,focused on endocrine therapy ... a leading Canadian specialty pharmaceutical company, announced ... the transactions under their,previously announced purchase and ...
... 1, 2008 Piedmont Heart Institute (PHI),expands its ... practice, Cardiology of Georgia, P.C. (COG), through a ... With eight,locations including Buckhead, Canton, Fayetteville and North ... the Piedmont Heart Institute and an,important addition to ...
Cached Biology Technology:VWR International, LLC Acquires Jencons (Scientific) Ltd, UK 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 3Piedmont Heart Institute Welcomes Cardiology of Georgia 2Piedmont Heart Institute Welcomes Cardiology of Georgia 3Piedmont Heart Institute Welcomes Cardiology of Georgia 4
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
(Date:10/15/2014)... Gutenberg University Mainz (JGU) as a full member, ... maintain a significant nationwide standing in the field ... Johannes Gutenberg University Mainz as a full member ... national and international competition for the best minds ... be proud that Mainz University has been recognized ...
(Date:10/15/2014)... have linked increased resistance to bacterial pneumonia in female ... hormone estrogen. , Females are naturally more resistant to ... scientists has shown that increased resistance to bacterial pneumonia ... oxide synthase 3 (NOS3). They also show that this ... female sex hormone estrogen. , The team, lead by ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... seen the story in the news before. Whether it,s the death ... in August, or of an elderly woman gardening in the middle ... condition for which there is no treatment beyond submersion in ice ... to a normal temperature. But, in a new ...
... of what living cells do is carried out by "molecular ... carry out some biological function. How the minute steps of ... a favorite target for creationists. In a study published ... a team of scientists from the University of Chicago and ...
... warmest since global climate has been measured, and while ... plant communities that reflect this warming trend, no study ... until now. With the publication of "Continent-wide ... Advance Online Publication (AOP) in Nature Climate Change ...
Cached Biology News:'Couch potato pill' might stop heat stroke too 2'Couch potato pill' might stop heat stroke too 3Evolution of complexity recreated using 'molecular time travel' 2Evolution of complexity recreated using 'molecular time travel' 3Evolution of complexity recreated using 'molecular time travel' 4European mountain vegetation shows effects of warmer climate 2